OASMIA: AMERICAN VETERINARIANS SEE THE FUTURE IN DRUG CANDIDATE PACLICAL® VET

NGM: OASM A)

This weekend Oasmia Pharmaceutical AB presented clinical results for Paclical®
Vet at the annual Veterinary Cancer Society Congress in Florida. 

Paclical® Vet is a cancer drug for dogs. Henrik von Euler, principal
investigator 
presented the results in Florida for the gathered American veterinary elite. 

Lisa Barber, Section Head at Tufts University, Massachusetts, is impressed:
- Dr. von Euler's research is very exciting. The tumor responses he presented
are truly impressive. We're all aware that paclitaxel has significant antitumor
effects, but as veterinary oncologists, we've been frustrated by the
limitations of hypersensitivity reactions to the solvent previously seen.
Paclical® Vet which is a novel micelle formulation of paclitaxel has great
potential for making important strides in treating dogs with a variety of
cancers, says Barber. 

Oasmia see the great success at the congress as an additional step further the
American market. 


More information is available at www.ngm.se or www.oasmia.com
Media contact: Maria Lundén +46 (0) 18 50 54 40 e-mail: info@oasmia.com 

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases. 
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase. Oasmia is listed on NGM Eguity.